Chemomab Therapeutics (CMMB) Total Non-Current Liabilities (2018 - 2025)
Chemomab Therapeutics posted quarterly Total Non-Current Liabilities of $179000.0 for Q1 2025, down 36.07% year-on-year from $280000.0 in Q1 2024, and down 14.35% on a QoQ basis from $209000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) has 8 years of Total Non-Current Liabilities data on file, last reported at $179000.0 in Q1 2025.
- For the quarter ending Q1 2025, Total Non-Current Liabilities fell 36.07% year-over-year to $179000.0; the trailing twelve-month figure through Mar 2025 stood at $179000.0 (down 36.07% YoY), and the FY2024 full-year result was $209000.0, down 33.86% from the prior year.
- Total Non-Current Liabilities for Q1 2025 stood at $179000.0, down from $209000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $328000.0 in Q1 2021 and bottomed at $5000.0 in Q3 2023.
- The 5-year median for Total Non-Current Liabilities is $209000.0 (2024), against an average of $194588.2.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities plunged 95.76%; it then jumped 4500.0% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $237000.0 in 2021, then tumbled by 61.6% to $91000.0 in 2022, then soared by 247.25% to $316000.0 in 2023, then slumped by 33.86% to $209000.0 in 2024, then slipped by 14.35% to $179000.0 in 2025.
- The last three Total Non-Current Liabilities figures came in at $179000.0 (Q1 2025), $209000.0 (Q4 2024), and $230000.0 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 209,000.00 |
| Sep 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 251,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 316,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 62,000.00 |
| Dec 31, 2022 | 91,000.00 |
| Sep 30, 2022 | 118,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Mar 31, 2022 | 203,000.00 |
| Dec 31, 2021 | 237,000.00 |
| Sep 30, 2021 | 298,000.00 |
| Jun 30, 2021 | 320,000.00 |
| Mar 31, 2021 | 328,000.00 |
| Dec 31, 2020 | 358,000.00 |
| Dec 31, 2019 | 725,000.00 |
| Sep 30, 2019 | 6.26 Mn |
| Jun 30, 2019 | 2.93 Mn |
| Mar 31, 2019 | 5.68 Mn |
| Dec 31, 2018 | 210,000.00 |